Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 192
- Registration Number
- NCT02952924
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Grafton, New Zealand
🇸🇬National University Health System, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT02951767
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 177
- Registration Number
- NCT02951429
- Locations
- 🇳🇱
Vu Medisch Centrum; Afdeling Longziekten, Amsterdam, Netherlands
🇹🇷Yedikule Gogus Hastaliklari ve Gogus Cerrahisi EAH;Gogus Hastaliklari, Istanbul, Turkey
🇿🇦University of Stellenbosch; Respiratory Research, Parow, South Africa
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT02928393
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇫🇷CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, France
🇫🇷Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, France
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1004
- Registration Number
- NCT02928406
- Locations
- 🇪🇪
North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia
🇨🇭Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie, Geneve, Switzerland
🇨🇭Luzerner Kantonsspital; Medizinische Onkologie, Luzern, Switzerland
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 202
- Registration Number
- NCT02924883
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
- Conditions
- Asthma
- Interventions
- Drug: MSTT1041ADrug: Placebo
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 517
- Registration Number
- NCT02918019
- Locations
- 🇺🇸
Genesis Clinical Research & Consulting, LLC, Fall River, Massachusetts, United States
🇨🇦Cheema Research, Mississauga, Ontario, Canada
🇺🇸Emerald Coast Research Associates, Panama City, Florida, United States
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02915224
- Locations
- 🇬🇷
Attiko Hospital; Haematology Clinic, Athens, Greece
🇬🇷General Hospital G. Papanikolaou; Hematology, BMT Unit, Thessaloniki, Greece
🇬🇷AXEPA Pathology Section; A Pathology Clinic, Thessaloniki, Greece
Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT02913482
- Locations
- 🇺🇸
Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois, United States
🇵🇱Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology, Gda?sk, Poland
🇺🇦Ams of Ukraine; Inst. of Neurology, Psychiatry & Narcology, Kharkov, Ukraine
A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
- Conditions
- Small Cell Lung Cancer
- Interventions
- Drug: RO7051790
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT02913443
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇨🇦The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada
🇪🇸Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain